Polycomb genes are associated with response to imatinib in chronic myeloid leukemia
| العنوان: | Polycomb genes are associated with response to imatinib in chronic myeloid leukemia |
|---|---|
| المؤلفون: | Francesco Crea, Sara Barsotti, Mario Petrini, Hui Hsuan Liu, Sara Galimberti, Riccardo Morganti, Claudia Baratè, Giulia Fontanelli, Marialuisa Polillo, Francesca Guerrini, Romano Danesi, Cheryl D. Helgason, Federica Ricci, Yuzhuo Wang, Pier Luc Clermont, Elena Ciabatti, Antonello Di Paolo |
| المصدر: | Epigenomics. 7:757-765 |
| بيانات النشر: | Future Medicine Ltd, 2015. |
| سنة النشر: | 2015 |
| مصطلحات موضوعية: | Adult, Male, Cancer Research, Time Factors, medicine.drug_class, Polycomb-Group Proteins, Biology, Tyrosine-kinase inhibitor, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, hemic and lymphatic diseases, Genetics, medicine, pharmacoepigenetics, Humans, Protein Kinase Inhibitors, neoplasms, Genotyping, Survival analysis, Aged, Aged, 80 and over, Polycomb Repressive Complex 1, Models, Genetic, Gene Expression Regulation, Leukemic, Reverse Transcriptase Polymerase Chain Reaction, Myeloid leukemia, Imatinib, Middle Aged, BMI1, Survival Analysis, Polycomb, Treatment Outcome, Imatinib mesylate, medicine.anatomical_structure, imatinib, CBX7, CBX6, Imatinib Mesylate, Cancer research, Female, Bone marrow, Research Article, medicine.drug |
| الوصف: | Aim: Imatinib is a tyrosine kinase inhibitor that has revolutionized the treatment of chronic myeloid leukemia (CML). Despite its efficacy, about a third of patients discontinue the treatment due to therapy failure or intolerance. The rational identification of patients less likely to respond to imatinib would be of paramount clinical relevance. We have shown that transmembrane transporter hOCT1 genotyping predicts imatinib activity. In parallel, Polycomb group genes (PcGs) are epigenetic repressors implicated in CML progression and in therapy resistance. Patients & methods: We measured the expression of eight PcGs in paired pre- and post-imatinib bone marrow samples from 30 CML patients. Results: BMI1, PHC3, CBX6 and CBX7 expression was significantly increased during imatinib treatment. Post-treatment levels of CBX6 and CBX7 predicted 3-month response rate. Measurement of post-treatment BMI1 levels improved the predictive power of hOCT1 genotyping. Conclusion: These results suggest that the expression levels of PcGs might be useful for a more accurate risk stratification of CML patients. |
| تدمد: | 1750-192X 1750-1911 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::243a1f9748f0f4e87fad1256d1c47be8Test https://doi.org/10.2217/epi.15.35Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....243a1f9748f0f4e87fad1256d1c47be8 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 1750192X 17501911 |
|---|